Inflammation Research

, Volume 62, Issue 5, pp 471–481 | Cite as

Activation of inflammatory cells and cytokines by peptide epitopes in vitro: a simple in-vitro screening assay for prioritizing them for in-vivo studies

  • Lakshmi A. Mundkur
  • Meenakshi Varma
  • Hemapriya Shivanandan
  • Dhanush Krishna
  • Kiran Kumar
  • Xinjie Lu
  • Vijay. V. Kakkar
Original Research Paper

Abstract

Objective

Antigen-specific immune modulation is an attractive approach to atherosclerosis treatment. The aim of this study was to develop an in-vitro assay to screen peptide molecules for their inflammatory propensity.

Materials

Human dendritic cells derived from CD14+ monocytes were activated using peptides derived from apolipoprotein B100 (ApoB), heat shock protein 60 (HSP60) and complement cascade (peptide A) in vitro, and used for priming autologous T cells. Proliferation of T cells, their differentiation to regulatory cells (Treg) and their cytokine profile were studied. The efficacy of the peptides in preventing atherosclerosis was studied in ApoBtm2Sgy/Ldlrtm1Her/J knockout mice.

Results and conclusion

ApoB and HSP60 peptides induced T-cell proliferation and expansion of regulatory T cells with interleukin-10 and transforming growth factor-β secretion. In comparison, peptide A was a poor stimulator of T cells and was found to induce tumor necrosis factor-α secretion by activated T cells. ApoB and HSP60 peptides were found to reduce early atherosclerotic lesion formation in mice by 32.1 and 33.5 %, respectively, while the reduction with peptide A was 5.7 %. Thus the in-vitro assay shows an apparent correlation with in-vivo activity and can be developed as a screening assay to prioritize the candidate molecules for animal efficacy testing.

Keywords

Atherosclerosis Inflammation Dendritic cells T-regulatory cells Cytokines Vaccine 

Notes

Acknowledgments

We gratefully acknowledge the support of the trustees of Thrombosis Research Institute, London and Bangalore, Tata Social Welfare Trust, India (TSWT/IG/SNB/JP/Sdm) and Department of Biotechnology, Ministry of Science and Technology, Government of India (BT/01/CDE/08/07). The sponsors did not participate in the design, conduct, sample collection analysis and interpretation of the data or in the preparation, review or approval of the manuscript. The authors have no conflicts of interest to disclose.

Supplementary material

11_2013_599_MOESM1_ESM.docx (248 kb)
Supplementary material 1 (DOCX 247 kb)

References

  1. 1.
    Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508–19.PubMedCrossRefGoogle Scholar
  2. 2.
    Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134:33–46.PubMedCrossRefGoogle Scholar
  3. 3.
    Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation. 2009;119:3133–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127:89–97.PubMedCrossRefGoogle Scholar
  5. 5.
    Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, et al. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:946–52.PubMedCrossRefGoogle Scholar
  6. 6.
    van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R, et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation. 2006;114:1968–76.PubMedCrossRefGoogle Scholar
  7. 7.
    van Puijvelde GH, van Es T, van Wanrooij EJ, Habets KL, de Vos P, van der Zee R, et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2677–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Hansson GK, Nilsson J. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin Immunopathol. 2009;31:95–101.PubMedCrossRefGoogle Scholar
  9. 9.
    Mundkur LA, Kakkar VV. Immune modulation as a therapeutic strategy for atherosclerosis. Curr Drug Ther. 2010;5:12.CrossRefGoogle Scholar
  10. 10.
    Nilsson J, Fredrikson GN, Bjorkbacka H, Chyu KY, Shah PK. Vaccines modulating lipoprotein autoimmunity as a possible future therapy for cardiovascular disease. J Intern Med. 2009;266:221–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J. 2005;26:1700–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Moser M, Murphy KM. Dendritic cell regulation of TH1–TH2 development. Nat Immunol. 2000;1:199–205.PubMedCrossRefGoogle Scholar
  13. 13.
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52.PubMedCrossRefGoogle Scholar
  14. 14.
    Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol. 2001;13:291–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3:984–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Farese RV Jr, Veniant MM, Cham CM, Flynn LM, Pierotti V, Loring JF, et al. Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc Natl Acad Sci U S A. 1996;93:6393–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179:1109–18.PubMedCrossRefGoogle Scholar
  18. 18.
    Hawkins ED, Hommel M, Turner ML, Battye FL, Markham JF, Hodgkin PD. Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data. Nat Protoc. 2007;2:2057–67.PubMedCrossRefGoogle Scholar
  19. 19.
    Quah BJ, Warren HS, Parish CR. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc. 2007;2:2049–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Milovanova TN. Comparative analysis between CFSE flow cytometric and tritiated thymidine incorporation tests for beryllium sensitivity. Cytom B Clin Cytom. 2007;72:265–75.CrossRefGoogle Scholar
  21. 21.
    Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today. 1999;20:561–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhou X, Caligiuri G, Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:108–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Schiopu A, Bengtsson J, Soderberg I, Janciauskiene S, Lindgren S, Ares MP, et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation. 2004;110:2047–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Gaofu Q, Jun L, Xin Y, Wentao L, Jie W, Xiuyun Z, et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol. 2005;45:591–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1708–15.PubMedCrossRefGoogle Scholar
  26. 26.
    Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:1095–100.PubMedCrossRefGoogle Scholar
  27. 27.
    Fredrikson GN, Andersson L, Soderberg I, Dimayuga P, Chyu KY, Shah PK, et al. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity. 2005;38:171–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Mottet C, Golshayan D. CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use. Swiss Med Wkly. 2007;137:625–34.PubMedGoogle Scholar
  29. 29.
    Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 2001;22:394–400.PubMedCrossRefGoogle Scholar
  30. 30.
    Roncarolo MG, Levings MK. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol. 2000;12:676–83.PubMedCrossRefGoogle Scholar
  31. 31.
    von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005;6:338–44.CrossRefGoogle Scholar
  32. 32.
    Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM. Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Lu X, Chen D, Endresz V, Xia M, Faludi I, Burian K, et al. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apob(tm2Sgy)Ldlr(tm1Her/J) mice. Atherosclerosis. 2010;212(2):472–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Lu X, Xia M, Endresz V, Faludi I, Mundkur L, Gonczol E, et al. Immunization with a combination of 2 peptides derived from the C5a receptor significantly reduces early atherosclerotic lesion in Ldlrtm1Her Apobtm2SgyJ mice. Arterioscler Thromb Vasc Biol. 2012;32(10):2358–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449:419–26.PubMedCrossRefGoogle Scholar
  36. 36.
    Aerts-Toegaert C, Heirman C, Tuyaerts S, Corthals J, Aerts JL, Bonehill A, et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol. 2007;37:686–95.PubMedCrossRefGoogle Scholar
  37. 37.
    Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.PubMedCrossRefGoogle Scholar
  38. 38.
    Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev. 2011;241:241–59.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel 2013

Authors and Affiliations

  • Lakshmi A. Mundkur
    • 1
  • Meenakshi Varma
    • 1
  • Hemapriya Shivanandan
    • 1
  • Dhanush Krishna
    • 1
  • Kiran Kumar
    • 1
  • Xinjie Lu
    • 2
  • Vijay. V. Kakkar
    • 1
    • 2
  1. 1.Thrombosis Research InstituteNarayana HrudayalayaBangaloreIndia
  2. 2.Thrombosis Research InstituteLondonUK

Personalised recommendations